Myriad foresight carrier screen5/7/2023 Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Additionally, Foresight offers the most extensively validated technology, which yields exemplary detection rates for the vast majority of genes on the panel (>99% across ethnicities) which means patients can trust both positive and negative results. The Foresight Universal Panel screens for 175+ clinically actionable conditions that gives meaningful information to patients and healthcare providers. The Myriad Foresight Carrier Screen is designed to maximize detection of couples at-risk for passing serious and prevalent conditions to children. Seven studies by Myriad were cited in the new statement, including those that demonstrate the clinical utility of carrier screening, reveal the limitations of an ethnicity-based approach, and establish a system of classifying the severity of genetic disease. Myriad Genetics has been a leader in establishing the evidence base for carrier screening and for developing inclusive products that serve patients of all ancestries. Screening without regard to ethnicity, as ACMG has recommended, avoids such inequity in care. For example, ethnicity-based screening guidelines identify only 6% of affected pregnancies among East Asians and 21% of affected pregnancies among Hispanics. The statement is partially based on a ground-breaking study by Myriad Genetics, published in the Journal of the American Medical Association, demonstrating that when carrier screening is limited to only certain ethnicities, a substantial number of pregnancies affected by serious genetic conditions fail to be identified. Additionally, ACMG recommends that insurers cover the costs of such tests, which will improve equitable patient access. The new recommendation statement makes ACMG one of the first medical societies to advise that carrier screening for conditions besides only cystic fibrosis and spinal muscular atrophy be offered as a first-line test for all potential parents, no matter their ethnicity. ACMG previously recommended more limited carrier screening and for only certain ethnicities. The statement recommends screening for more than 110 genetic disorders regardless of family history or ethnicity. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for a new recommendation statement by the American College of Medical Genetics and Genomics (ACMG), advising that genetic carrier screening be offered to all people who are pregnant or considering a pregnancy. SALT LAKE CITY, J(GLOBE NEWSWIRE) - Myriad Genetics, Inc.
0 Comments
Leave a Reply. |